

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Comparing the effect of probiotics with placebo on xerostomia in head and neck cancer patients undergoing radiation therapy

#### Protocol summary

##### Study aim

Comparison of unstimulated saliva flow in two probiotic and placebo groups  
Comparing the amount of stimulated saliva flow in two probiotic and placebo groups  
Comparison of dry mouth severity score (VAS) in two probiotic and placebo groups

##### Design

A controlled randomized trial, double blinded with a parallel group design of 82 patients (Phase 3).  
Randomization will be used by PASS program.

##### Settings and conduct

This study is conducted on patients with head and neck cancer who underwent radiotherapy in the last 1-3 months. After obtaining informed consent, these patients who referred to the Razi or Amirmomenin Hospitals in Rasht will be enrolled. Patients are randomly assigned to one of the two intervention or control groups and receive the corresponding code inside the sealed envelope and receive the corresponding drug from the hospital pharmacist.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: All head and neck cancer patients who have had 1-3 months of radiotherapy; A functional level equal to or higher than 80 according to the Karnovsky criterion  
Non-entry criteria: Any other type of oral disease; Inability to understand the questionnaire; Parkinson; Sjogren; Diabetes; Acquired immunodeficiency syndrome; Use of drugs affecting saliva; Pregnancy; Taking antibiotics or probiotics in the last month

##### Intervention groups

The participants of the intervention group receives a Lactogum troche before going to bed for 60 days. The mentioned drug is a product of Zist Takhmir company and contains the probiotic K12 and M18 strain of *Streptococcus salivarius*. The participants of the control group receives a placebo lozenge before going to bed for 60 days. The placebo is similar to Lactogum troche, but it does not contain probiotics.

##### Main outcome variables

volume of unstimulated saliva  
volume of stimulated saliva  
severity of xerostomia ( Visual Analog Scale; VAS)

#### General information

##### Reason for update

In the initial version of the protocol, the sample size was estimated using G\*Power based on an independent two-sample t-test, resulting in 64 participants per group. After a methodological revision and considering the correlated and serial structure of the continuous data, the statistical analysis was modified to a serial correlation model, which better aligns with the temporal nature of the data and the study objectives. Accordingly, the sample size was recalculated in G\*Power and reduced to 41 participants per group (with 80% power and a 0.05 significance level). This change was made to improve statistical precision and ensure better alignment with the final analysis approach, without affecting the scientific validity of the study. It is also noted that this modification has been approved by the university's research committee

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20081202001483N5**  
Registration date: **2022-08-03, 1401/05/12**  
Registration timing: **prospective**

Last update: **2025-07-15, 1404/04/24**

Update count: **1**

##### Registration date

2022-08-03, 1401/05/12

##### Registrant information

###### Name

Mir Mohammad Jalali

###### Name of organization / entity

Guilan University of Medical Sciences

###### Country

Iran (Islamic Republic of)

**Phone**

+98 13 1324 3085

**Email address**

mmjalali@gums.ac.ir

**Recruitment status**

**Recruitment complete**

**Funding source**

**Expected recruitment start date**

2022-09-01, 1401/06/10

**Expected recruitment end date**

2023-04-30, 1402/02/10

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparing the effect of probiotics with placebo on xerostomia in head and neck cancer patients undergoing radiation therapy

**Public title**

Investigating the effect of probiotics on dry mouth after radiotherapy

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

All head and neck cancer patients who had radiotherapy (after 1-3 months) Functional level equal to or higher than 80 according to the Karnofski criterion Absence of any other oral disease Inability to understand the questionnaire

**Exclusion criteria:**

Parkinson disease Sjögren's disease Taking drugs that affect the function of saliva Pregnancy Diabetes Acquired immune deficiency syndrome History of antibiotic use in the last 30 days Use of antifungal drugs or antiseptic mouthwashes

**Age**

From **18 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor

**Sample size**

Target sample size: **82**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

A statistician will generate independent allocation

sequences and randomisation lists using the Power Analysis & Sample Size (PASS) software. Randomization will be performed in blocks of 4 (2 placebo and 2 probiotic) (21 blocks). To ensure allocation concealment, an independent person will oversee the packaging and labelling of trial treatments based on the randomisation schedule at otorhinolaryngology research center of Guilan University of Medical Sciences (GUMS). Zist Takhmir company (Tehran, Iran) provides the probiotic and placebo; the group assignment list will be withheld until the final evaluation of the study data. All investigators, participants, and outcome assessors will be blinded to the assigned treatment throughout the study.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Probiotics and placebo are prepared by Zyst Takhmir and are similar in terms of color, size and dimensions and packages. All the following drugs have a special code and are given to patients by the hospital pharmacist based on the assigned code in the randomization process. Patients and researchers and people who evaluate the results will not know about the type of intervention.

**Placebo**

Used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

**1**

**Ethics committee**

**Name of ethics committee**

Ethics committee of Guilan University of Medical Sciences

**Street address**

Amiralmomenin Hospital, 17 Sharivar street, Bank Melli Square

**City**

Rasht

**Province**

Guilan

**Postal code**

4139638459

**Approval date**

2022-06-27, 1401/04/06

**Ethics committee reference number**

IR.GUMS.REC.1401.198

**Health conditions studied**

**1**

**Description of health condition studied**

Xerostomia

**ICD-10 code**

K11.7

**ICD-10 code description**

Disturbances of salivary secretion

**Primary outcomes**

**1**

**Description**

Volume of unstimulated saliva

**Timepoint**

At the beginning of the study (before the start of the intervention), at the end of 2 months and at the end of 3 months

**Method of measurement**

Measuring the amount of saliva for 5 minutes in unstimulated conditions

**2**

**Description**

Volume of stimulated saliva

**Timepoint**

At the beginning of the study (before the start of the intervention), at the end of 2 months and at the end of 3 months

**Method of measurement**

Measuring the amount of saliva for 5 minutes in stimulating conditions (using an applicator dipped in fresh lemon juice)

**3**

**Description**

Severity of xerostomia (Visual Analogue Scale; VAS)

**Timepoint**

At the beginning of the study (before the start of the intervention), at the end of 2 months and at the end of 3 months

**Method of measurement**

The patient chooses a score from 0 (absence of dry mouth) to 10 (worst degree of dry mouth) according to the severity of dry mouth.

**Secondary outcomes**

**1**

**Description**

Score of EORTC QLQ HN43

**Timepoint**

At the beginning of the study (before the start of the intervention), at the end of 2 months and at the end of 3 months

**Method of measurement**

using persian version of EORTC QLQ HN43 questionnaire

**Intervention groups**

**1**

**Description**

Intervention group: one probiotic lozenge (Lactogum) before going to bed for 60 days

**Category**

Treatment - Drugs

**2**

**Description**

Control group: one placebo lozenge before going to bed for 60 days

**Category**

Placebo

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Razi Hospital

**Full name of responsible person**

Dr Hamid Saeidi Saedi

**Street address**

Razi square, Sardare Jangal Blvd

**City**

Rasht

**Province**

Guilan

**Postal code**

4163934774

**Phone**

+98 13 3375 9662

**Email**

hamidsaedi53@yahoo.com

**2**

**Recruitment center**

**Name of recruitment center**

Amiralmomenin Hospital

**Full name of responsible person**

Dr Maryam Akbari

**Street address**

17 Sharivar street, Bank Melli square

**City**

Rasht

**Province**

Guilan

**Postal code**

4139638459

**Phone**

+98 13 3323 8307

**Email**

maryamakbari\_6699@yahoo.com

**Sponsors / Funding sources**

1

**Sponsor**

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Dr Mohammadreza Naghipour

**Street address**

Deputy of Research and Technology of Guilan  
University of Medical Sciences- in front of 17  
Shahrivar Hospital – Shahid Siadati Ave. – Namjoo St.

**City**

Rasht

**Province**

Guilan

**Postal code**

4144666949

**Phone**

+98 13 3333 6394

**Email**

naghi@gums.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Rasht University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Dr Maryam Akbari

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Ear, Nose, and Throat

**Street address**

17 sharivar street, Bank Mell square, Amiralmomenin  
Hospital

**City**

Rasht

**Province**

Guilan

**Postal code**

4139638459

**Phone**

+98 13 3323 8306

**Email**

maryamakbari\_6699@yahoo.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Dr Mir Mohammad Jalali

**Position**

Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Ear, Nose, and Throat

**Street address**

17 Sharivar street, Bank Melli square, Amiralmomenin  
Hospital

**City**

Rasht

**Province**

Guilan

**Postal code**

4139638459

**Phone**

+98 13 3323 8306

**Email**

mmjalali@gmail.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Dr Maryam Akbari

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Ear, Nose, and Throat

**Street address**

17 sharivar street, Bank Mell square, Amiralmomenin  
Hospital

**City**

Rasht

**Province**

Guilan

**Postal code**

4139638459

**Phone**

+98 13 3323 8306

**Email**

maryamakbari\_6699@yahoo.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**  
No - There is not a plan to make this available

**Statistical Analysis Plan**  
No - There is not a plan to make this available

**Informed Consent Form**  
No - There is not a plan to make this available

**Clinical Study Report**  
Yes - There is a plan to make this available

**Analytic Code**  
No - There is not a plan to make this available

**Data Dictionary**  
No - There is not a plan to make this available

**Title and more details about the data/document**  
In the case of individual patient data, all potential data will be shared after de-identifying individuals. The result of the clinical study will be published in the form of an article.

**When the data will become available and for how long**

The access period starts 6 months after publication of the results.

**To whom data/document is available**  
All researchers

**Under which criteria data/document could be used**  
For secondary data analysis and meta-analysis

**From where data/document is obtainable**  
Dr Mir Mohammad Jalali Otorhinolaryngology research center, Amiralmomenin HospitalAmiralmomenin Hospital,17 sharivar street, Bank Mell square, Rasht , Iran. 4139638459 Tel: 0098 13 33238306 Mobile: 0098 9111318776 Email: mmjalali@gmail.com

**What processes are involved for a request to access data/document**  
After receiving the applicant's request and a brief statement of the protocol in which the mentioned information is used, a preliminary review will be done and the information will be sent to the researcher within 2 weeks.

**Comments**